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Abstract: Glioblastoma multiforme (GBM) is the most devastating primary brain tumour characterised
by infiltrative growth and resistance to therapies. According to recent research, the sigma-1 receptor
(sig1R), an endoplasmic reticulum chaperone protein, is involved in signaling pathways assumed to
control the proliferation of cancer cells and thus could serve as candidate for molecular characterisation
of GBM. To test this hypothesis, we used the clinically applied sig1R-ligand (S)-(−)-[18F]fluspidine
in imaging studies in an orthotopic mouse model of GBM (U87-MG) as well as in human GBM
tissue. A tumour-specific overexpression of sig1R in the U87-MG model was revealed in vitro
by autoradiography. The binding parameters demonstrated target-selective binding according to
identical KD values in the tumour area and the contralateral side, but a higher density of sig1R in
the tumour. Different kinetic profiles were observed in both areas, with a slower washout in the
tumour tissue compared to the contralateral side. The translational relevance of sig1R imaging in
oncology is reflected by the autoradiographic detection of tumour-specific expression of sig1R in
samples obtained from patients with glioblastoma. Thus, the herein presented data support further
research on sig1R in neuro-oncology.
Keywords: sigma-1 receptor availability; orthotopic xenograft of glioblastoma in mouse; small animal
Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI); (S)-(−)-[18F]fluspidine;
imaging-based biomarker
1. Introduction
Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous
system. Although the global incidence is rare with less than 10 per 100,000 people, the median survival
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rates for patients with GBM remain dramatically low despite complex surgical, pharmacological and
radiation therapy approaches [1,2]. An important aspect contributing to this poor outcome is the
genetic heterogeneity of GBM, which translates into heterogeneous expression patterns of potentially
druggable targets [3]. Accordingly, the development of new targeted therapies as well as of biomarkers
for predictions of treatment response would benefit from an improved understanding of how such
spatiotemporal patterns evolve and change during pathogenesis [4–9]. Nuclear medicine imaging
techniques offer a unique possibility to noninvasively assess the distribution and amount of certain
biological targets and thus to contribute significantly to the drug-discovery process and later on to the
evaluation of the treatment efficacy [10–12].
By application of suitable radiolabeled molecules, positron emission tomography (PET) in
particular can assess such alterations with high sensitivity. Imaging agents for the investigation of the
catabolic and anabolic metabolism can detect cancer-specific alterations in high-capacity processes
such as glycolysis (by [18F]FDG), amino acid transport (by [11C]MET or [18F]FET), and membrane
turnover (by [18F]FMC) [13,14]. They are currently utilized to improve the clinical management of
brain cancer patients. Furthermore, the PET technology offers the principal possibility to investigate
differences in the expression pattern and activity of diagnostically and therapeutically relevant
proteins, such as receptors or enzymes, and to correlate them with tumour heterogeneity and
aggressiveness. The current development of radiolabelled probes to image e.g., isocitrate dehydrogenase
mutations (IDH1R132H) [15], or the glutamate carboxypeptidase II (prostate-specific membrane antigen,
PSMA) [16], reflects the interest in preclinical and clinical research on detailed and targeted molecular
characterisation of malignancies in the brain, which is a prerequisite to define the role of nuclear
medicine imaging for the individualized treatment of patients with GBM [14,17].
Our research on the identification of new targets for brain cancer imaging focuses on the sigma-1
receptor (sig1R), an intracellular chaperone protein highly expressed in a variety of cancers including
GBM [18,19]. Under physiological conditions, the sig1R is localized at the mitochondrion-associated
endoplasmic reticulum membrane (MAM) and at the plasma membrane and is involved by interactions
with other proteins in a number of pathways related to the metabolism and proliferation of cells.
Accordingly, albeit at different levels, sig1R is expressed in all peripheral organs as well as in the
central nervous system. Widely distributed in the brain [20], the sig1R is involved in memory,
emotional, and sensory functions and changes in its expression are related to neurodegenerative
diseases such as Huntington ’s disease and Alzheimer’s disease, as well as in stroke, depression and
pain disorders [20,21]. Most likely, due to the translocation of the intracellular receptor from MAM to the
plasma membrane and the cell nucleus, which is triggered under pathological conditions [22–25], sig1R
is functionally involved into a variety of cellular pathways related to stress response and survival [25–27].
In addition, the expression of sig1R seems to be upregulated by cancer-specific mechanisms, as indicated
by the high levels of sig1R protein discovered in many cancer cell lines [19,26–28]. The antiproliferative
effect of pharmacological inhibition of sig1R by putative antagonistic ligands on cancer cell lines further
substantiates the potential role of sig1R in cancer biology [27,29–33]. Sig1R ligands influence apoptosis,
migration, and cell cycle progression pathways through their interaction with voltage-dependent
K+ channels, volume-regulated Cl− channels, or endoplasmic reticulum Ca2+ release [22,31,32,34].
Altogether, the available data present strong evidence of an important role of sig1R in tumour
biology, and for that reason, PET noninvasive molecular imaging of sig1R is assumed to improve our
understanding of the role of this particular protein in tumour pathophysiology and to promote the
development of a sig1R-targeted-therapies [35].
Already different radiotracers have been developed to investigate the expression of sig1R by
PET such as [18F]FMSA4503 [36], [18F]SFE or [18F]FTC-146 [37,38]. However, only [11C]SA4503 and
(S)-(−)-[18F]fluspidine were applied in research on the in vivo imaging of sig1R in brain tumours using
heterotopic brain tumour models, as by the group of van Waarde, or orthotopic models, as by our
group [39,40].
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Encouraged by the approval of the in-house developed radiopharmaceutical (S)-(−)-[18F]fluspidine
for clinical trials (EudraCT Numbers: 2014-005427-27, 2016-001757-41), the promising results of a
collaborative pilot study in an orthotopic mouse model of GBM [40], and the establishment of orthotopic
brain tumour models in our group, we decided to investigate further the relevance of sig1R in brain
cancer biology and to evaluate the potential of (S)-(−)-[18F]fluspidine-PET to characterise brain tumours
on a molecular level. We report herein on the assessment of GBM-specific expression of sig1R by a
combination of in vitro and in vivo approaches using mice bearing intracranial U87-MG tumours as a
preclinical orthotopic model of human GBM and the sig1R-specific radioligand (S)-(−)-[18F]fluspidine.
Initially, we validated the in vivo selectivity of (S)-(−)-[18F]fluspidine for sig1R in a sig1R-knockout
mouse model. Then, we validated by radioligand binding assays the suitability of the U87-MG cell
line used for the orthotopic GBM model regarding the presence of the target, and confirmed by
autoradiography the unimpaired overexpression under in vivo conditions. By immunohistochemistry
as radioligand-independent method, we could confirm the expression and overexpression of sig1R
protein in U87-MG cells in 2D culture as well as in the cellular environment of the mouse brain. Finally,
we performed dynamic PET/MRI (magnetic resonance imaging) studies to assess the pharmacokinetics
of (S)-(−)-[18F]fluspidine in the orthotopic U87-MG mouse model of human GBM, and report on
the very first detection of sig1R protein in human GBM tissue by means of in vitro autoradiography,
validating the relevance of this target.
2. Results
2.1. Expression of sig1R in U87-MG Cells
2.1.1. Expression of sig1R in U87-MG Cells in 2D Cell Culture
We initially evaluated the expression of sig1R in U87-MG cells, a human primary glioblastoma
cell line, grown in 2D cell culture by radioligand binding assays and immunohistochemistry to
determine their suitability for the intended orthotopic mouse model of GBM. By a single saturation
assay using (+)-[3H]pentazocine, an established sig1R-specific radioligand, a Bmax value of 129 fmol/mg
protein and a KD value of 2.4 nM was determined. Specific binding of (S)-(−)-fluspidine towards
(+)-[3H]pentazocine-labeled binding sites in U87-MG cells has been proven by displacement studies,
and the affinity of (S)-(−)-[18F]fluspidine to sig1R has been determined with a KD of 16.7 nM.
To verify the identity of the specific binding site of the two radioligands by an independent
method, we further performed immunohistochemistry using a sig1R-specific antibody. The thereby
determined cytoplasmic staining of protein in isolated U87-MG cells, which corresponds with the
labelling of sig1R in the positive control HEK-293 cells overexpressing human sig1R, is demonstrated
in Figure 1A, B, respectively.
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Figure 1. Immunofluorescent staining of sigma-1 receptors (sig1R). Representative image of the 
sig1R staining (A) in U87-MG cells grew in vitro, (B) in HEK-293 cells overexpressing human sigma-1 
receptor (hsig1R) grew in vitro and (C) in a cryosection of U87-MG tumour cells orthotopically 
Figure 1. Immunofluorescent staining of sigma-1 receptors (sig1R). Representative image of the sig1R
staining (A) in U87-MG cells grew in vitro, (B) in HEK-293 cells overexpressing human sigma-1 receptor
(hsig1R) grew in vitro and (C) in a cryosection of U87-MG tumour cells orthotopically implanted in a
mouse brain (scale bar: 25 µm, x40, green channel: sig1R staining, blue channel: nucleus staining).
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2.1.2. Expression of sig1R in U87-MG Cells Grown In Vivo
Because transplantation of human cancer cells into mice might be associated with an altered
expression profile due to the significant change in the microenvironment, we subsequently
investigated orthotopically implanted U87-MG tumour cells by immunohistochemistry and radioligand
binding studies.
The strong immunofluorescence signal determined in tumour cells in cryosections obtained from
mouse brain at day 27 after intracerebral transplantation of U87-MG cells indicates the persistently high
expression of sig1R in the orthotopic GBM (Figure 1C). Besides, the fluorescent staining is informative
in that not all cells in the field of view express sig1R, indicating a heterogeneous expression profile
within the tumour bulk (Figure 1C). Thus, the conservation of sig1R expression irrespective of the
environment (culture medium or brain dynamic environment) was confirmed (Figure 1).
Complementary autoradiography performed with the sig1R-specific PET tracer
(S)-(−)-[18F]fluspidine confirmed the expression of sig1R in orthotopically growing U87-MG
cells. The autoradiographic images presented in Figure 2 indicate a high density of binding
sites in the tumour region (Figure 2B). The radioactive signal is nearly completely abolished
by co-administration of the sig1R-specific ligand SA4503, a selective agonist commonly used as
competitive agent (IC50 = 17.4 nM [41]) (Figure 2C). Interestingly, the macroscopic distribution
pattern of (S)-(−)-[18F]fluspidine in the orthotopic tumour reflects a heterogeneous accumulation
of activity within the tumour, similar to what was observed by immunohistochemistry on cellular
level. By saturation studies, performed as homogenous radioligand displacement experiments
by co-incubation of (S)-(−)-[18F]fluspidine with different concentrations of (S)-(−)-fluspidine,
we determined the kinetic binding parameters of (S)-(−)-[18F]fluspidine in the tumour (T) and an
internal reference region, the contralateral striatum (CL). In both regions, (S)-(−)-[18F]fluspidine
bound specifically and with comparable affinities of KD, T = 17.5 ± 1.3 nM and KD, CL = 17.0 ± 4.8 nM.
However, the sig1R density was ~1.7 times higher in the tumour area compared to the CL area,
as reflected by values of Bmax, T = 704 ± 16 fmol/mg protein vs. Bmax, CL = 414 ± 36 fmol/mg protein.
Molecules 2020, 25, x FOR PEER REVIEW 4 of 17 
 
implanted in a mouse brain (scale bar: 25 µm, x40, green channel: sig1R staining, blue channel: 
nucleus staining). 
2.1.2. Expression of sig1R in U87-MG Cells Grown In Vivo  
Because transplantation of human cancer cells into mice might be associated with an altered 
expression profile due to the significant change in the microenvironment, we subsequently 
investigated orthotopically implanted U87-MG tumour cells by immunohistochemistry and 
radiolig nd binding studies. 
The strong immunofluorescence signal determi ed in tum ur cells in cryos ctions obtained 
from mouse brain at day 27 after intracerebral transplantation of U87-MG cells indicates the 
persistently high expression of sig1R in the orthotopic GBM (Figure 1C). Besides, the fluorescent 
staining is infor ative in that not all cells in the field of view express sig1R, indicating a 
heterogeneous expression profile within the tumour bulk (Figure 1C). Thus, the conservation of 
sig1R expression irrespective of the environment (culture medium r brai  dynamic environment) 
was co firmed (Figure 1). 
Comple entary autoradiograp y perf rmed with the sig1R-specific PET tracer 
(S)-(−)-[18F]fluspidine confir ed the expression of sig1R in orthot pically growing U87-MG cells. 
The autoradiographic images presented in Figure 2 indicate a high density of binding sites in the 
tumour region (Figure 2B). T e radioactive signal is nearly completely abolished by 
co-administration of the sig1R-specific ligan  SA4503, a selective agonist commonly used as 
competitive agent (IC50 = 17.4 nM [41]) (Figure 2C). Interestingly, the macroscopic distribution 
pattern of (S)-(−)-[18F]fluspidine in the orthotopic tumour reflects a heterogeneous accumulation of 
activity within the tumour, similar to what was observed by immunohistochemistry on cellular 
level. By saturation studies, performed as homogenous radioligand displacement experi ents by 
co-incubation of (S)-(−)-[18F]fluspidine with different concentratio s of (S)-(−)-fluspidine, we 
determined the kinetic binding parameters of (S)-(−)-[18F]fluspidine in the tumour (T) and an internal 
reference region, the contralateral striatum (CL). In both regions, (S)-(−)-[18F]fluspidine bound 
specifically and with comparable affinities of KD, T = 17.5 ± 1.3 nM and KD, CL = 17.0 ± 4.8 nM. 
However, the sig1R density was ~1.7 times higher in the tumour area compared to the CL area, as 
reflected by values of Bmax, T = 704 ± 16 fmol/mg protein vs. Bmax, CL = 414 ± 36 fmol/mg protein. 
 
Figure 2. In vitro autoradiography of the mouse brain bearing an orthotopic U87-MG xenograft. 
Representative autoradiographic images of the coronal plane of mouse brain slices: (A) 
Hematoxylin-eosin staining; (B) in vitro distribution of activity after incubation with 0.1 MBq/mL 
(S)-(−)-[18F]fluspidine, (C) co-incubation with 10 µM SA4503 to determine the nonspecific binding 
and (D) with 10 nM of (S)-(−)-fluspidine as competing agent. Cx: cortex; CL: contralateral striatum; 
Th: thalamus; Hy: hypothalamus; T: tumour. Width of a mouse brain ~1 cm. 
Figure 2. In vitro autoradiography of the mouse brain bearing an orthotopic U87-MG
xenograft. Representative autoradiographic images of the coronal plane of mouse brain slices:
(A) H matoxylin-eosin staining; (B) in vitro distribution of activity after incubation with 0.1 MBq/mL
(S)-(−)-[18F]fluspidine, (C) co-incubation with 10 µM SA4503 o determine the nonspecific binding and
(D) with 10 nM of (S)-(−)-fluspidine as competing agent. Cx: cortex; CL: contralateral striatum; Th:
thalamus; Hy: hypothalamus; T: tumour. Width of a mouse brain ~1 cm.
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2.2. Assessment of GBM-Specific (S)-(−)-[18F]Fluspidine Kinetics In Vivo by Dynamic Small-Animal PET
Imaging Studies
2.2.1. Additional Approval of Target Specificity of (S)-(−)-[18F]Fluspidine PET
Due to access to a limited number of sig1R-knockout mice [42], we performed a single head-to-head
dynamic PET study with (S)-(−)-[18F]fluspidine in sig1R-knockout (n = 1) and control (n = 3) mice with
the main focus on the tracer kinetics in the striatum. Mean injected activity was 3.5 MBq and 1.9 MBq
with a molar activity of 24 GBq/µmol and 21 GBq/µmol at the time of injection, resulting in a mean
chemical concentration of 4.7 nmol/kg and 3.2 nmol/kg in the control group and the sig1R-knockout
mouse respectively. The corresponding time-activity curves (TACs) are presented in Figure 3. Both the
sig1R-knockout and the control animals showed a rapid uptake of activity within the first minutes
after i.v. injection of (S)-(−)-[18F]fluspidine (initial peak between 1 and 2 min p.i. of 1.45 and 1.12 SUV,
respectively) along with a much stronger and faster washout observed in the sig1R-knockout mouse in
comparison to the control animals (SUV at 10, 20, and 40 min p.i. of 0.84, 0.64, and 0.25 vs. 1.07, 1.03,
and 0.67, respectively) confirming the selectivity in vivo of (S)-(−)-[18F]fluspidine for sig1R (Figure 3A).
In order to correct for potential model-related differences in the brain perfusion, we calculated an SUV
ratio (SUVR) from the TAC data obtained in striatum and blood at each time points. The corresponding
SUVR curves, presented in Figure 3B, indicate for both animal models nearly stable SUVR values at
15 to 60 min p.i., albeit with clearly different values. While for the control animals SUVR values in
the range of 0.8 to 1 (corresponding to an area under the curve (AUC) value of 48.6 ± 8.3) has been
estimated, the notably lower value of about 0.4 (corresponding to an AUC value of 23.4) determined in
the single sig1R-knockout mouse confirms the target specificity of (S)-(−)-[18F]fluspidine.
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Figure 3. Positron Emission Tomography/ Magnetic Resonance (PET/MR) imaging of control mice (n = 3)
and of sig1R-knockout mouse (n = 1) after i.v. administration of (S)- −)-[18F]fl spidine. (A) Average
striatal time-activity curves for control mice (black squares) and sig1R-knockout mouse (orange dots).
(B) Average time-varying SUVRs of the striatum over the blood (defined from the image-derived
input function (idif)) of control mice (black squares) and sig1R-knockout mouse (orange dots) (C)
Average time-varying SUV of the blood (defined from the idif) of control mice (black squares) and
sig1R-knockout mouse (orange dots).
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2.2.2. GBM-Specific Pharmacokinetics of (S)-(−)-[18F]Fluspidine in the Orthotopic U87-MG
Mouse Model
Encouraged by the in vitro and in vivo findings on the specific expression of sig1R in orthotopically
grown U87-MG tumours and the sig1R-specific binding of (S)-(−)-[18F]fluspidine, we proceeded with
PET studies with (S)-(−)-[18F]fluspidine performed under baseline conditions in nude mice-bearing
orthotopic U87-MG (n = 3). Mean injected activity was 9.1 MBq with a molar activity of 92.5 GBq/µmol
at the time of injection, resulting in a mean chemical concentration of 4.2 nmol/kg. The tumour growth
was assessed by MRI with a T2-weighted sequence, and a 60 min dynamic PET scan, followed by T1-
and T2-weighted sequences, performed when the tumour size was 28 ± 8 mm3 (i.e., 23 to 30 days after
implantation). The regions-of-interest (ROIs) were delineated on the T2-weighted MR images and then
applied on the PET data to generate the regional TACs.
As reflected by the TACs presented in Figure 4, although not statistically significant, the uptake of
(S)-(−)-[18F]fluspidine in the tumour is lower and more slowly than the activity uptake in the control
region with maximal SUV values of 0.82 at 3 min p.i. and 1.24 at 1 min p.i., respectively. However,
because the washout from the tumour was slower, the tumour and CL TACs intersected at about
30 min p.i., demonstrating with SUVs of 0.38 and 0.28 at 60 min p.i. a higher retention of activity
in the tumour region compared to the CL, respectively. The retarded washout of the sig1R-specific
(S)-(−)-[18F]fluspidine from the orthotopic tumour is in accordance with the autoradiographic data,
indicating a higher availability of sig1R in the U87-MG tumour tissue in comparison to CL.
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Figure 4. PET/MR imaging of sig1R in mice with orthotopic xenograft of human GBM cells (U87-MG).
Average time-activity curves after i.v. administration of (S)-(−)-[18F]fluspidine of the tumour (red dots)
and the contralateral (black squares) regions of interest (n = 3). Statistical test: Student t-test, * p < 0.05.
The intratumoral heterogeneity of sig1R expression already discovered by the radioligand and
antibody investigations in vitro was detectable also by the in vivo imaging study. The early PET images
between 2 and 9 min after injection show an heterogeneous uptake of (S)-(−)-[18F]fluspidine into the
tumour (Figure 5D, upper panel). According to the histological analyses of the explanted tumour
tissue, performed immediately after the PET scans, the tumour inner part is characterised by a lower
cell density compared to the periphery along with extra-cellular oedema area highlighting presumably
areas of necrosis (Figure 5A–C). Therefore, the heterogeneous uptake of (S)-(−)-[18F]fluspidine may
also (or additionally) be caused by reduced blood supply to the tumour centre. The PET image at later
time points (45 to -60 min p.i.; Figure 5D, lower panel) pictures a more homogenous uptake of the
tracer, along with a low slope, reflecting an accumulation.
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2.3. Presence of (S)-(−)-[18F]Fluspidine Binding Sites in Human GBM Tissue
To initially assess the suitability of sig1R as specific target for molecular characterisation of human
GBM, we performed in vitro autoradiography with (S)-(−)-[18F]fluspidine using cryosections of tissue
samples obtained from 3 patients diagnosed with Glioblastoma multiforme IV. Total and nonspecific
binding of the PET ligand was determined by incubation with only (S)-(−)-[18F]fluspidine or with
co-administration of a high concentration of haloperidol to block the sig1R, followed by histological
staining of the respective cryosections. As shown in Figure 6, the autoradiographic images indicate a
heterogeneous pattern of binding sites of (S)-(−)-[18F]fluspidine in all three GBM samples with the
highest density in regions histologically characterised by a high density of cells which we assume might
be related to the highly proliferating tumour cells. Accordingly, although it was not possible within
this preliminary study to confirm by immunohistochemistry the distribution pattern of sig1R in the
cryosections or to identify the type of cells possessing high specific binding of (S)-(−)-[18F]fluspidine,
these preliminary data motivate us to design a complementary study on the investigation of sig1R
protein in a larger number of GBM samples by means of specific radioligands and antibodies.
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Figure 6. Sig1R autoradiography with the sig1R-specific PET ligand (S)-(−)-[18F]fluspidine in human
GBM in vitro. Binding of (S)-(−)-[18F]fluspidine at 4.5 nM in cryosections (12 µm) of tumour tissue
obtained from three patients (A,B,C) demonstrated heterogeneous distribution throughout the slices.
By co-incubation with 1 µM haloperidol (D,E,F), a substantial reduction in activity accumulation was
obtained. Histochemical a alysis of corresponding sections was erformed by Nissl staining (G,H,I).
Analysi of o e sample at higher magnification (red square in C) demonstrated correlation of the
activity accumulation (K) with highly cell dense regions (H&E staining: (L); Nissl stai ing: (M). Length
of the biopsies samples ~1 cm.
3. Discussion
In this study, we evaluated the availability of sig1R in an orthotopic mouse model of human GBM.
High expression of sig1R in different cancer cell lines derived from prostate, breast, colon, melanoma,
small and non-small cell lung cancer, brain tumours including GBM, neuroblastoma, and meningioma
have already been reported [18,19,26,27,43–48]. The involvement of sig1R in many but selective protein
interactions, the antiproliferative effect of putative antagonists, as well as their nonpleiotropic effects
make sig1R a potent drug target prone to overcome adaptative drug resistance alone or in combination
with other drugs [49,50]. It is also known that the upregulation of sig1R on both mRNA and protein
level in the same cancer subtype differs from one cell line to another and from one patient to another,
probably reflecting a context-dependent expression of sig1R [51–53]. Consequently, an improved
understanding of how such patterns evolve and change during pathogenesis, by the use of noninvasive
PET imaging, would promote the development of sig1R-based therapies. In this context, we chose to
evaluate by PET the suitability of the clinically approved imaging agent (S)-(−)-[18F]fluspidine for the
analysis of the expression of sig1R in GBM.
We first investigated in vitro the level of expression of sig1R protein in U87-MG cells, a human
GBM cell line widely applied for orthotopic brain cancer mouse models. As consistently reported, sig1R
is located at the endoplasmic reticulum-mitochondria interface and redistributes ligand-mediated
and under conditions of cellular stress dynamically to the plasma membrane and the nucleus
envelope [54,55]. The examination of sig1R expression in U87-MG cells by using (+)-[3H]pentazocine,
a selective sig1R ligand widely applied in radioligand binding assays [56,57], demonstrated high
affinity binding towards a single binding site expressed in U87-MG cells grown in 2D cell culture.
The density of sig1R in this cell line, Bmax = 129 fmol/mg protein, is in the range of values determined by
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(+)-[3H]pentazocine in other cancer cell lines such as 42 fmol/mg protein in the C6 murine glioblastoma
cells, 76.5 fmol/mg protein in the NB41A3 neuroblastoma cells or 1115 fmol/mg protein in the U-138-MG
cells [19]. We identified the U87-MG cells as suitable for the orthotopic GBM model applied in this study.
As the microenvironment is known to influence gene expression, e.g., the hypoxia-stimulated
HIF-1α expression in glioma or the culture mode (2D vs. 3D)-dependent differential gene expression
of colorectal cell lines [58–61], we further investigated the expression of sig1R in the intracerebral
U87-MG tumour. The comparable immunofluorescence staining on 2D-cultivated U87-MG cells and
on the orthotopically grown U87-MG tumour along with the similarity of the KD values of the PET
tracer (S)-(−)-[18F]fluspidine, indicate the conservation of sig1R expression and conformation over the
translation from in vitro culture to in vivo implantation. Furthermore, the cytoplasmic localization of
the sig1R fluorescence signal which was observed in vitro and in the explanted brain tumours matches
with the cellular localization of the receptor found in rat astrocytes and mouse neurons [62,63].
Subsequently, we quantified the number of sig1R expressed in the U87-MG tumours implanted in
the right striatum as well as in the internal control region, the left striatum. The equivalent KD values
obtained for (S)-(−)-[18F]fluspidine in both regions indicate that the PET radiotracer binds to the same
target, i.e., the sig1R, in both compartments. The analysis of the binding parameter Bmax excludes
conformational differences between sig1R in cancer and normal cells, as discussed by Kim et al., as a
possible reason for the higher accumulation of sig1R-targeting radioligands in tumour tissue, but clearly
indicates an about 2-fold higher density of sig1R in the U87-MG tumour in comparison to the healthy
brain [51]. Thus, the herein exploited orthotopic U87-MG GBM mouse model is appropriate for the
following imaging studies. As an add-on to the extensive and validated data on the selectivity of
the clinically applied PET radioligand (S)-(−)-[18F]fluspidine obtained mainly by pharmacological
intervention studies [64,65], we made use of access to a sig1R-knockout mouse model to measure the
actual contribution of the off-target binding of the radiotracer to the uptake of activity in the brain in
imaging studies in mouse [66]. In accordance with the fast washout kinetics observed in the knockout
model, we supposed only a weak background signal in imaging studies with (S)-(−)-[18F]fluspidine in
the orthotopic brain cancer model and no relevant interaction with off-target binding sites in vivo.
Eventually, the results of the fundamental characterisation of the components of the experimental
setting, i.e., the mouse model and the PET radioligand, with respect to availability of and selectivity to
sig1R, prompted us to proceed with dynamic PET studies in the orthotopic U87-MG glioblastoma mouse
model. Only few studies have explored the use of PET radiotracers for sig1R imaging of tumours, and
even less have addressed brain tumours in particular [36,39,67–70] such as the investigation of sig1R
in an ectopic glioma rat model as well as in spontaneous pituitary tumours in rats using [11C]SA4503
by the group of van Waarde [39,69,70]. To the best of our knowledge, we are the first exploring the
sig1R availability of human glioblastoma in an orthotopic tumour mouse model. The in vivo imaging
studies revealed a tumour-to-background ratio (TBR) of only slightly higher than 1, detectable from
the late PET images. Even though we observed a continuous washout of activity from the tumour, this
process was slower than in contralateral tissue. Accordingly, the activity concentration in the tumour
surpassed that in the contralateral striatum over time.
Despite this, the TBR value determined in our study is in fact notably lower than the values
reported for the [11C]SA4503 PET studies mentioned above. However, we assume that this discrepancy
is related mainly to the characteristics of the background region, in particular the physiological
expression of sig1R in the different grafting sites. An ectopic tumour obtained by e.g., implantation of
C6 glioma in the shoulder in the soft tissue [71], close to the muscle, benefit of an ideal background
tissue with low expression of sig1R [20], leading to a TBR values > 4. Such values are not comparable
to orthotopically transplanted brain tumours due to the comparatively high expression of sig1R in
the surrounding nondiseased brain, as indicated by e.g., in the herein performed PET studies with
(S)-(−)-[18F]fluspidine in healthy mice [72,73].
The reasons for the discrepant results obtained in the present paper regarding the in vitro and
in vivo quantification of sig1R in the U87-MG tumours are not clear at the moment. We assume, that
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factors such as microenvironment, vascularisation, or interstitial fluid pressure affect the binding
parameters of (S)-(−)-[18F]fluspidine in vivo. The U87-MG tumour is known to be highly vascularised
and presenting necrotic foci [62], suggesting a first uptake in the vascularised periphery and a later
accumulation by diffusion in the core of the tumour tissue. However, a systematic investigation of these
processes was beyond the scope of this study. Notwithstanding this limitation, a detailed investigation
of the PET images of the intracranial U87-MG tumours revealed that the heterogeneous pattern of
activity accumulation discovered already in vitro could be detectable by the in vivo imaging approach
as well. Interestingly, a similar distribution of [11C]SA4503 in the tumour outer rim was reported in
the already mentioned PET study of the ectopic C6 glioma model as well as in a patient with non-small
cell lung cancer in the tumour tissue [74,75]; noteworthy is the discrepancy between the distribution
patterns of [11C]SA4503 and [18F]FDG [69,74]. Since [18F]FDG PET images may be misleading due to
an increased glucose metabolism in noncancerous but inflammatory tissues, the authors suggested the
use of sig1R PET imaging to discriminate between tumour and inflammation [69].
A final aspect addressed in this study on the suitability of PET imaging of sig1R in glioblastoma was
the investigation of the expression of sig1R in human GBM tissue. The accordingly performed receptor
autoradiography with (S)-(−)-[18F]fluspidine on cryosections of human glioblastoma obtained from
three patients consistently showed a heterogeneous distribution of binding sites of the sig1R-targeting
radioligand with high-density binding in cell-dense regions as suggested by the subsequent histological
analysis. However, although sig1R appears to play a role in proliferation, this preliminary examination
does not allow to speculate about a correlation between receptor expression and tumour proliferation
but nevertheless suggests to design a respective large-scale study [28].
4. Materials and Methods
All experimental work including animals has been conducted in accordance with
the national legislation on the use of animals for research (Tierschutzgesetz (TierSchG),
Tierschutz-Versuchstierverordnung (TierSchVersV)) and has been approved by the responsible research
ethics committee (TVV 30/17; TVV 18/18 Landesdirektion Sachsen).
4.1. Radiochemistry
Enantiomerically pure (S)-(−)-[18F]fluspidine was prepared on a TRACERlab FXN synthesizer
(GE Healthcare, Waukesha, WI, USA) as described in previous publications [65]. The radiochemical
purity of (S)-(−)-[18F]fluspidine was >99%, and the molar activity (Am) at the end of the synthesis
(EOS) was 89–180 GBq/µmol (n = 2).
4.2. Cell Culture
U87-MG cells (obtained from Jens Pietzsch/Birgit Belter, Department Radiopharmaceutical and
Chemical Biology, Helmholtz-Zentrum Dresden-Rossendorf, Rossendorf, Germany) and human
hsig1R-transfected Human Embryonic Kidney (HEK) cells (obtained from Olivier Soriani, Institut de
Biologie Valrose—University Côte d’Azur, Sophia Antipolis, France) were maintained in monolayer
culture (37 ◦C, 5% CO2, 95% O2) in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Invitrogen,
Dun Laoghaire, Ireland) supplemented with 10% heat inactivated fetal bovine serum (Gibco, Invitrogen,
Dun Laoghaire, Ireland), 5% penicillin and streptomycin, 1.25% sodium pyruvate, 1% l-glutamine
(Gibco, Invitrogen, Ireland) and 1 µg/mL puromycin (Gibco, Invitrogen, Dun Laoghaire, Ireland) only
for the transfected cells.
4.3. In Vivo Competitive Radioligand Binding Assay
Cell membrane homogenates of U87-MG cells were obtained by gentle scraping the cells grown
to confluency in one 175 cm2 flask, followed by sedimentation of the cells suspended in cell culture
medium by centrifugation at 800 rpm for 3 min at room temperature, re-suspension of the cells in
1 mL 50 mM TRIS-HCl, pH 7.4/4 ◦C and incubation on ice for 20 min, centrifugation of the suspension
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at 15,000 rpm for 15 min at 4 ◦C, and finally re-suspension of the pellet in 200 µL 50 mM TRIS-HCl,
pH 7.4/4 ◦C and storage at −25 ◦C. The radioligand binding assay was performed by incubating the
U87-MG cell membrane homogenate (226 µg protein/mL) with the Sig1R agonist (+)-[3H] pentazocine
(working concentration = 3.25 nM; Am = 995 GBq/mmol; PerkinElmer LAS GmbH, Rodgau, Germany)
in incubation buffer (50 mM TRIS-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2)
without (total binding, TB; n = 3) or with co-incubation of 1 µM haloperidol (nonspecific binding, NB;
n = 3) at room temperature for 60 min. The incubation was terminated by filtration via a Whatman®
glass microfibre filter (Grade GF/B, pre-incubated in freshly prepared polyethyleneimine (3%) at room
temperature for 90 min), followed by quadruplicate washing with 50 mM TRIS-HCl, pH 7.4/4 ◦C
using a semi-automated cell harvester (48-samples; Brandel, Gaithersburg, MD, USA). Filter-bound
radioactivity was detected in terms of DPM/vial by liquid scintillation counting (Beckman LS 6500;
Beckman Coulter Inc., Fullerton, CA, USA) of the isolated filters immersed for two hours in liquid
scintillation cocktail (Ultima Gold; PerkinElmer LAS GmbH, Rodgau, Germany). Specific binding (SB)
was calculated by SB (DPM/vial) = TB (DPM/vial) − NB (DPM/vial). The Bmax and the KD values were
estimated by a nonlinear regression model (equation: one-site binding (hyperbola)) using GraphPad
Prism, Version 4.1 (GraphPad Inc., La Jolla, CA, USA).
4.4. In Vitro Autoradiography on Human Glioblastoma Tissue
Cryosections of brain tumour tissue from three patients (Glioblastoma multiforme IV) were
obtained using a microtome (MICROM HM560, Fisher Scientific GmbH, Schwerte, Germany), mounted
on microscopy slides (SuperFrost, Thermo Scientific Menzel, Fisher Scientific GmbH, Schwerte,
Germany), dried for ~2 h at room temperature, and stored at −25 ◦C until the autoradiography study.
For the experiment, the slides were taken out from the freezer, the cryosections dried under a stream of
cold air, and pre-incubated with incubation buffer (50 mM TRIS-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl,
2 mM CaCl2, 1 mM MgCl2) at room temperature for 15 min. The pre-incubation solution was decanted,
the slices dried again under a stream of cold air, and covered afterwards with the incubation solution
((S)-(−)-[18F]fluspidine, 197 kBq/mL incubation buffer = 4.5 nM at the time of incubation, without (total
binding) or with co-incubation with 1 µM haloperidol to assess nonspecific binding). Incubation at
room temperature was terminated after 60 min, the slides were washed two times in 50 mM TRIS-HCl,
pH 7.4 at 4 ◦C, on ice for two minutes each followed by dipping in ice-cold demineralized water for 5 s
and rapid drying under a stream of cold air. Afterwards, the slides were exposed to a phosphor imager
plate (BAS-IP TR 2025, FujiFilm Corporation, Tokyo, Japan) along with standards obtained by pipetting
and drying 1 µL of each concentration of a serial dilution of the radioligand solution on to a microscopic
slide. The exposed phosphor-imaging plates were scanned using a high resolution scanner (HD-CR 35
Bio; Dürr NDT GmbH & Co. KG, Bietigheim-Bissingen, Germany) at a laser spot size of 12.5 µm (pixel
size: 12.5 µm2) followed by two-dimensional analysis of the digitized images (AIDA 4.27; Elysia-raytest
GmbH, Straubenhardt, Germany). The tracer distribution in the autoradiographic images obtained for
total and nonspecific binding was compared by visual inspection and correlated with the histochemical
staining (Nissl- and Hematoxiline-eosin staining) of the corresponding tissue sections.
4.5. In Vitro Autoradiography on Mice Brain-Bearing Glioblastoma
Cryosections of brains obtained from female athymic nude mice (Rj:NMRI-Foxn1 nu/nu)
(10–12 weeks old, 25–38 g), were obtained as described above. The same protocol as in Section 4.3
was used. The incubation step was performed with 0.1–0.2 MBq/mL (S)-(−)-[18F]fluspidine in buffer
for 60 min at room temperature. Nonspecific binding was determined in the presence of 10 µM
of SA4503 (Tocris, Bio-Techne GmbH, Wiesbaden-Nordenstadt, Germany) or 100 µM to 10 nM of
(S)-(−)-fluspidine, respectively. Developed autoradiographs were analysed in a phosphor imager
(HD-CR 35; Dürr NDT GmbH & Co. KG, Bietigheim-Bissingen, Germany). The quantification was
performed by using 2D-densitometric analysis (AIDA 2.31 software; raytest Isotopenmessgeräte GmbH,
Straubenhardt, Germany). The Bmax and the KD values were estimated by a linear regression model
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(equation: one-site binding (hyperbola)) using GraphPad Prism, Version 4.1 (GraphPad Inc., La Jolla,
CA, USA).
4.6. Immunohistochemistry
Tissues were cryopreserved by incubation in 2-Methylbutane at −25 ◦C (Merck, Germany).
The brains were cut into coronal sections 10 µm thickness with cryostat (MICROM HM560, Fisher
Scientific GmbH, Schwerte, Germany) and kept at −25 ◦C. Immunostaining was performed after
fixation in PFA 4% for 20 min at 4 ◦C of the slides. Detection of the sig1R protein was performed
by overnight incubation at 4 ◦C of the slides with the primary mouse monoclonal antibody (1:500 in
blocking buffer 5% normal goat serum, B-5: sc-137075, Santa Cruz Biotechnology, Inc., Dallas, TX, USA).
After washing with a solution of 1% BSA in PBS, the slides were incubated for 1 h at room temperature
with the secondary polyclonal goat anti-mouse antibody (1:200 in dilution buffer 1% BSA, Alexa Fluor
® 488; ab150117, Abcam, Berlin, Germany). A Hoechst counterstaining, 10 min at room temperature,
was performed to visualize the nuclei of the cells (1:1000 in PBS, Hoechst 33258, Life Technologies,
Carlsbad, Ca, USA). After a step of washing and drying, slides were cover up with mounting medium.
(Aquapolymount, Polysciences Europe GmbH, Hirschberg an der Bergstrasse, Germany). Visualization
of the slides was performed by fluorescence microscopy (Leica, DMi8, software Leica LASX, Leica
Mikrosysteme Vertrieb GmbH, Wetzlar, Germany).
4.7. Animals and Orthotopic Brain Tumour Model
Female athymic nude mice (Rj:NMRI-Foxn1 nu/nu) were chosen for this study (Janvier labs, France).
The mice were used for tumour implantation at the age of 8 weeks (26–30 g). During microsurgery
mice were anesthetized with a mixture of air and isoflurane concentrate (1.5–2% depending on the
breathing) under sterile conditions. The mice were placed into a Stoelting stereotactic frame (just for
mouseTM, Stoelting Europe, Dublin, Ireland). A midline incision was done and a burr hole was drilled
0.5 mm anterior and 2.5 mm lateral to the bregma. 5 × 104 U87-MG cells were suspended in 1 µL
Hank’s Buffered Salt Solution (HBSS, 1X) and were injected 3.0 mm into the brain parenchyma with
a flow of 0.1 µL/min using a 10 µL Hamilton syringe. After injection, the burr hole was filled with
bonewax (Ethicon, US, LLC), the scalp incision sutured (Vicryl 6.0, Ethicon, US, LLC) and the surface
antiseptically cleaned. Animal sacrifice was performed by induction of anesthesia with a mixture of air
and isoflurane concentrate followed by cervical dislocation.
4.8. Small Animal PET/MR Imaging
For the time of the experiments, female CD-1 mice (n = 3; age: 10 weeks; weight: 30–35 g) or nude
mice (n = 3; age: 10 weeks; weight: 25–30 g) (Janvier Labs, Le Genest-Saint-Isle, France) and one CD-1
sig1R-knockout mouse (n = 1; age: 10 weeks; weight: 27 g) (Envigo RMS, SARL, Bresso, Italy) were kept
in a dedicated climatic chamber with free access to water and food under a 12:12h dark:light cycle at a
constant temperature of 24/26 ◦C. The animals were anaesthetized (Anaesthesia Unit U-410, AgnTho’s,
Lidingö, Sweden) with isoflurane (1.8%, 0.35 L/min) delivered in a 60% oxygen/40% air mixture (Gas
Blender 100 Series, MCQ instruments, Rome, Italy) and maintained at 37 ◦C with a thermal bed
system. (S)-(−)-[18F]fluspidine was injected into the lateral tail vein (control group: 3.5 ± 1.9 MBq,
Am: 94 ± 7 GBq/µmol EOS; hsig1R-knockout mouse: 1.9 MBq; Am: 89 GBq/µmol EOS; tumour group:
5.7 ± 3.7 MBq; Am: 119 ± 41 GBq/µmol EOS) followed by a 60 min PET/MR scan (nanoScan®, Mediso,
Hungary). Each PET image was corrected for random coincidences, dead time, scatter and attenuation
(AC), based on a whole body (WB) MR scan. The list mode data were sorted into sonograms using a
framing scheme of 12 × 10 s, 6 × 30 s, 5 × 300 s, 9 × 600 s. The reconstruction parameters for the list
mode data are: 3D-ordered subset expectation maximization (OSEM), 4 iterations, 6 subsets, energy
window: 400–600 keV, coincidence mode: 1–5, ring difference: 81. The mice were positioned prone
in a special mouse bed (heated up to 37 ◦C), with the head fixed to a mouth piece for the anesthetic
gas supply with isoflurane in 40% air and 60% oxygen. The animal head was positioned in the center
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of the field of view in order to benefit from the highest spatial resolution possible (spatial resolution
center of the FOV: 900 µm). A dynamic PET scan of a duration of 60 min was performed followed
by a T2 weighted sequence (Fast Spin Echo, TR/TE: 4377/88.5 ms, NEX: 4, FOV: 70 × 70 mm, matrix:
256 × 256, SI: 0.9 mm) and a T1 weighted sequence (Gradient Echo, TR/TE: 15/2.59 ms, NEX: 4, FOV:
60 × 60 mm, matrix: 160 × 160, slice thickness: 0.5 mm) for anatomical orientation and AC correction
respectively. Image registration and evaluation of the region of interest (ROI) was done with PMOD
(PMOD Technologies LLC, v. 3.9, Zurich, Switzerland). The respective brain regions were identified
using the T2 weighted sequence and the tumour area and the contralateral area were delineated
manually. The hypersignal due to the tumour in T2 weighted images was manually segmented and
described as “tumour ROI”, and due to the compression of the contralateral side a fixed circled shape
ROI was used to delineate the striatum avoiding nearby structure (cortex, ventricles, hypothalamus).
The image-derived input function (IDIF) was extracted from a voxel of interest (VOI) segmented on the
inferior vena cava (IVC). The IVC was identified using the first time frames showing the first passage
of (S)-(−)-[18F]fluspidine bolus. An automatic algorithm from PMOD was used to identify the IVC
signal avoiding heart and kidney area [76]. The activity data are expressed as mean standardized
uptake value (SUV) of the overall ROI or as SUV ratio of the striatum ROI over the IDIF (SUVR). Data
are presented as mean ± standard deviation (SD). Microsoft Excel was used to perform statistical tests.
A parametric student t-test preceded by a Fischer test for variance were used to compare the groups
with p < 0.05.
5. Conclusions
To conclude, we showed for the first time in an orthotopic GBM model, the U87-MG mouse model
of glioblastoma and the suitability of a sig1R-targeting PET radioligand, (S)-(−)-[18F]fluspidine, to
investigate the tumour-specific expression pattern of sig1R by in vivo imaging. Whether the inferior
outcome in vivo in comparison to in vitro is caused by the physiological expression of sig1R in the
healthy brain or by certain pathophysiological characteristics of the orthotopic mouse model of GBM,
remains to be elucidated. Nevertheless, this first evaluation of the sig1R availability in an orthotopic
in vivo model of brain tumour contributes to a better understanding of this model and suggests
an expression of sig1R in the tumour periphery as found in other studies, which may be related to
proliferation and invasiveness. In conclusion, the data obtained in the U87-MG mouse model of GBM
along with the detection of sig1R in human GBM tissue for the first time by a PET radioligand, indicate
not only the relevance of this target but also the suitability of (S)-(−)-[18F]fluspidine for sig1R-targeted
cancer research and drug development.
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